🎉 We are incredibly proud to announce that our co-founders have made the cover of #NatureBiotechnology this month with their groundbreaking article, “Discovery of sparse, reliable omic biomarkers with Stabl,” published in January 2024! This is a significant achievement for Julien Hedou, Grégoire Bellan, Dyani Gaudilliere, Franck Verdonk, Xavier Durand, Brice Gaudilliere, and all the co-authors. Their dedication to advancing bioinformatics with Stabl is helping shape the future of predictive analytics in multi-omic research. #Stabl leverages cutting-edge algorithms to identify the most predictive features within complex multi-omic datasets. This breakthrough promises to significantly impact bioinformatics by facilitating the translation of scientific discoveries into real-world clinical applications, streamlining decision-making processes, and enhancing predictive analytics across various industries. 💡 We are also thrilled to highlight our Creative Director, Clara Leibenguth, whose stunning design was selected for the cover! This milestone reflects the hard work and passion of our team at Surge, and we couldn’t be prouder of this accomplishment! 📖 You can read the full article in open access here: https://lnkd.in/egSuxkB2. 👉 If you’d like to test Stabl on your data, feel free to contact us at info@surge.care. For more information about our technologies, visit biomics.app.
SurgeCare
Hôpitaux et services de santé
Façonner l'avenir de la santé de précision en décryptant le système immunitaire.
À propos
Nous croyons que l'identification du profil immunitaire peut révolutionner l'amélioration du parcours chirurgical pour des millions de patients. En combinant des technologies innovantes avec l'intelligence artificielle, notre équipe multidisciplinaire de cliniciens, d'ingénieurs et de scientifiques se concentre sur l'amélioration globale des normes de soins. Prédire les risques de complications avant une intervention chirurgicale est crucial pour personnaliser les interventions cliniques préopératoires, prendre des décisions chirurgicales éclairées et améliorer les résultats chirurgicaux. En effet, environ 30% des interventions chirurgicales majeures entraînent des complications dans les 30 jours suivant l'opération, telles que des infections, une pneumonie voire un décès. Chez Surge, notre approche repose sur plus de sept années de recherche clinique, scientifique et translationnelle menée par notre équipe à l'Université Stanford. Notre test associe l'évaluation à l'échelle des cellules individuelles du système immunitaire avant une chirurgie avec les données cliniques disponibles dans les dossiers médicaux électroniques grâce à un algorithme d'apprentissage automatique propriétaire. Les systèmes immunitaires individuels sont évalués de manière exhaustive à partir d'un simple échantillon sanguin prélevé avant l'intervention et analysé par cytométrie de masse. Notre méthode nous permet de simuler le traumatisme chirurgical en laboratoire avec une petite quantité de sang contenant des millions de cellules immunitaires avant la chirurgie. Nous utilisons cette technique pour comprendre précisément la réponse de chaque cellule immunitaire de votre corps au traumatisme et ainsi prédire de manière précise les résultats postopératoires.
- Site web
-
https://www.surge.care
Lien externe pour SurgeCare
- Secteur
- Hôpitaux et services de santé
- Taille de l’entreprise
- 2-10 employés
- Siège social
- Paris
- Type
- Société civile/Société commerciale/Autres types de sociétés
- Fondée en
- 2021
- Domaines
- Machine Learning, Biomarkers, AI et Multiomics
Lieux
-
Principal
Paris, FR
-
San Francisco, US
Employés chez SurgeCare
-
Dominique BLANCHARD
Directeur Recherche et Innovation - Transformer les avancées scientifiques en produits innovants
-
Alex Schweitzer
VP of Partnerships @Surge.care 🧬
-
Dyani Gaudilliere
Chief, Dental Medicine & Surgery - Stanford University School of Medicine | Co-Founder, Member of the Scientific & Clinical Advisory Board - Surge
-
Valentin Picot
Co-founder and COO @Surge.care 🧬 | Immunological fingerprinting technology | Deliver accurate predictions for complication-free surgeries |…
Nouvelles
-
SurgeCare a republié ceci
We are thrilled to share that SurgeCare has been honored with a prestigious award from the Fondation Force pour l'Innovation et la Recherche en Santé! At the 2024 Trophées ceremony, our project, Surgelab, was spotlighted as one of six groundbreaking innovations in #diagnostic, #prognostic, and #theranostic fields. This accolade is a key recognition of our commitment to advancing healthcare and improving patient outcomes through cutting-edge solutions. 🌟 We extend our heartfelt gratitude to the Fondation Force, under the leadership of Professor Jean SIBILIA, Lilla Merabet, and Nobel Laureate Professor Jules Hoffmann for recognizing our efforts to decrypt the immune system and supporting us with a generous grant. This funding will be pivotal in driving our research and development forward. A huge congratulations to all the other laureates for their exceptional contributions: 📣 BrightSens Diagnostics: John Volke, Andrey Klymchenko, Elisabete Silva 📣 SUPERBRANCHE: Delphine Felder-Flesch, Richard BOUAOUN 📣 IPHC - Institut Pluridisciplinaire Hubert Curien - CNRS: Dimitri Heintz 📣 Inserm Institute for Translational Medicine and Liver Disease, University of Strasbourg: Emilie Crouchet, Catherine Schuster 📣 Icube: Jonathan Vappou, Gangi Afshin 📣 Solence : Clara Stephenson, Mael Mertad We are excited about the journey ahead and the positive impact Surgelab will bring to the healthcare sector. Stay tuned for more updates on our progress! #Innovation #Healthcare #Surgelab
-
Surge advances further in its pursuit of decrypting the immune system to drive precision medicine, with our successful fundraising of €7.5 million ✨ This fundraising round, led by Eurazeo and bolstered by the support of new and old strategic partners including : Boutique Venture Partners, HCVC, 50 Partners Santé, Kima Ventures, MH Innov' and Yann Fleureau, propels us closer to our ambitious objectives. We are positioned to launch of our first product, #PreCyte®, for predicting the risk of postoperative complications, and our premier laboratory, #SurgeLab™, for acquiring individualized immune signatures. Join us on this journey to unlock the secrets of the immune system and redefine precision medicine!🔥 #Surge #PrecisionMedicine #Stabl #Healthcare
-
🔍 Exciting Career Opportunity at Surge! We're Hiring an R&D Laboratory Technician 🧬 Join the Surge Team in Revolutionizing Patient Care! At Surge, we're deeply committed to advancing personalized medicine through our cutting-edge research in immune system analysis. We're seeking a skilled Laboratory Technician to join our R&D team in Paris and contribute to our pioneering work. 🔬About the Role: • Engage actively in our research projects aimed at deciphering the immune system. • Use innovative single-cell immune analysis technologies (mass and/or flow cytometry). • Process patient or animal blood samples • Contribute to the development of our research platform. Ideal Candidate: • Expertise in cytometry and experience in processing blood samples. • Proven track record in laboratory excellence and GLP. • Strong team player with initiative and excellent analytical skills. • Fluent in both French and English. 📆 Hiring in Q1 2024 | Location: Paris 📩 Ready for the challenge? Apply at HR@surge.care and/or DM 📄 Detailed Job Position Description Attached Be a part of something big at Surge!
-
📣 Exciting Breakthrough in Precision Medicine We at Surge are thrilled to extend our sincerest congratulations to Julien Hedou, Ivana Maric, Grégoire Bellan, Jakob Einhaus, Dyani Jones, Franck Verdonk, Xavier Durand, Brice Gaudilliere, and their esteemed co-authors on their groundbreaking publication in Nature Biotechnology. 🔬 The manuscript, titled "Discovery of sparse, reliable omic biomarkers with Stabl," introduces an innovative algorithm that promises to revolutionize predictive diagnostics and therapeutic development. This aligns closely with the pioneering spirit and the core vision of Surge - Shaping the future of precision health by decrypting the immune system 🧬 Stabl's remarkable ability to discern the most predictive biological features from a wealth of multi-omic data is a leap forward towards true precision medicine. The success of #Stabl in various clinical scenarios from predicting pregnancy complications to identifying immune signatures of surgical site infections is a testament to the power of multidisciplinary collaboration. It is inspiring to see how collective expertise across fields can lead to such transformative outcomes. We are excited about the future possibilities this opens up, not just for Surge, but for the entire field of medicine. We look forward to the potential collaborations and the shared journey ahead in advancing patient care and treatment. Congratulations once again to all the authors for this remarkable achievement! For those interested, you can find the manuscript in open access in the first comment! #PrecisionMedicine #AI #Healthcare #NatureBiotechnology #Stabl #Surge #NBT